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Human respiratory syncytial virus (HRSV) is a major cause of acute lower respiratory infections (ALRIs) in children worldwide. The clinical outcomes vary from mild respiratory tract infections to severe bronchiolitis and pneumonia ([@B1]). Annually, more than 30 million episodes of HRSV-associated ALRIs occur globally in children under 5 years of age ([@B1]). Currently, there is no available vaccine against HRSV. Genome-based characterization of HRSV allows for better understanding of its global diversity and provides information for the development of vaccines, antivirals, and diagnostics ([@B2]). HRSV is a member of the family Paraxymoviridae and subfamily Pneumovirinae ([@B3]). It is an enveloped virus with a 15-kb negative-sense single-stranded RNA genome that encodes 11 viral proteins ([@B3]). HRSVs are divided into two groups (A and B) based on their antigenic variability. Thirteen HRSV-A genotypes and 20 HRSV-B genotypes have been identified on the basis of the G protein diversity ([@B4]). HRSV-A infections are more common than HRSV-B infections. This antigenic variability contributes to the repeated infections that occur throughout life ([@B5]).

The isolate RSVA/Lebanon/14LJF289/2015 (JF289) was collected in Lebanon from an infant who presented to the emergency room with an acute respiratory illness during the 2014/2015 HRSV season. The patient had no history of palivizumab use. RNA extraction was performed using a Purelink virus RNA/DNA kit followed by first-strand cDNA synthesis with an RSV-specific primer and SuperScript III reverse transcriptase. Purification of the cDNA was performed using Agencourt AMPure XP beads followed by double-stranded DNA synthesis with a Sigma SeqPlex XE kit. The libraries were prepared with a NEBNext fast library prep kit, and ion sphere particles were generated using the Ion OneTouch 2 system. Sequencing was carried out on the Ion Proton sequencer. The obtained sequences were trimmed and assembled using Geneious software, and the gaps were filled by using the primer-walking method and Sanger sequencing.

The genome of JF289 contains 15,098 nucleotides, including a 3′ leader and 5′ trailer. The 11 open reading frames (ORFs) encoding viral proteins include two nonstructural proteins (NS1and NS2), a nucleocapsid protein (N), a matrix protein (M), a phosphoprotein (P), an attachment protein (G), a fusion protein (F), a small hydrophobic protein (SH), transcription elongation factors (M2-1 and M2-2), and a large protein (L). The contents of A, U, G, and C were 38.91%, 27.69%, 15.65%, and 17.74%, respectively. BLAST analysis revealed the highest similarity with RSVA/USA/TH_10323/2013 with 99% identity. JF289 possessed an N276S substitution in the F protein, which has been associated with partial resistance to palivizumab and may lead to further mutations leading to complete resistance ([@B6], [@B7]).

The sequence of the G protein was aligned with other HRSV-A sequences retrieved from GenBank, and a phylogenetic tree was constructed using the neighbor-joining method with MEGA version 6.0. Based on the tree analysis, JF289 belongs to the recently identified ON1 genotype that has emerged globally since 2010. ON1 has a 72-nucleotide duplication within the G protein's second hypervariable region. The increase in frequency of the ON1 genotype worldwide suggests an ability of this genotype to escape host immunity and sustain transmission.
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The complete genome of the RSVA/Lebanon/14LJF289/2015 virus was deposited in GenBank under the accession number [MG793382](https://www.ncbi.nlm.nih.gov/nuccore/MG793382).
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